[A22-69] Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V
Last updated 17.10.2022
Project no.:
A22-69
Commission:
Commission awarded on 12.07.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Alone or in combination with methotrexate for the treatment of active enthesitis-associated arthritis in patients aged 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-08 | Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A15-20 | Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A15-53 | Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-78 | Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-79 | Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-80 | Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-68 | Secukinumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |